Larvol Delta - Cerecor-has-launched-a-c--Phase-1b-clinical-trial-NCT04752371-of-the--human-mAb-CERC007-targeting-IL18-in-12-patients-with-active-adult-onset-Stills-disease-AOSD-They-estimate-AOSD-affects-3500--7000-in-the-US-3400--6900-pts-in-Europe-httpstcoDlW1QbXOG0

CERC-007 - Cerecor

May 14, 2021